首页> Blood advances> Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma.

Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma.

导出 LinkOut

翻译打印收藏纠错

第一作者： Frederick L,Locke

第一单位： Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL.

作者： Frederick L,Locke ^[1] ; John M,Rossi ^[2] ; Sattva S,Neelapu ^[3] ; Caron A,Jacobson ^[4] ; David B,Miklos ^[5] ; Armin,Ghobadi ^[6] ; Olalekan O,Oluwole ^[7] ; Patrick M,Reagan ^[8] ; Lazaros J,Lekakis ^[9] ; Yi,Lin ^[10] ; Marika,Sherman ^[2] ; Marc,Better ^[2] ; William Y,Go ^[2] ; Jeffrey S,Wiezorek ^[2] ; Allen,Xue ^[2] ; Adrian,Bot ^[2]

作者单位： Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL. ^[1] Kite, a Gilead Company, Santa Monica, CA. ^[2] Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX. ^[3] Hematologic Oncology Treatment Center, Dana-Farber Cancer Institute, Boston, MA. ^[4] Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA. ^[5] Division of Oncology, Washington University School of Medicine, St. Louis, MO. ^[6] Division of Hematology and Oncology, Vanderbilt-Ingram Cancer Center, Nashville, TN. ^[7] Department of Medicine, Hematology/Oncology, University of Rochester School of Medicine, Rochester, NY. ^[8] Department of Hematology/Oncology, University of Miami Health System, Sylvester Comprehensive Cancer Center, Miami, FL; and. ^[9] Division of Hematology, Mayo Clinic, Rochester, MN. ^[10]

医学主题词抗原, CD19(Antigens, CD19);生物制品(Biological Products);人类(Humans);免疫疗法, 过继(Immunotherapy, Adoptive);炎症(Inflammation);肿瘤负荷(Tumor Burden)

DOI 10.1182/bloodadvances.2020002394

PMID 33035333

发布时间 2021-12-04

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Blood advances

2020年4卷19期

4898-4911页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

点击下载本期目录封面

Blood advances

2020年4卷19期

4898-4911页

检索历史清除

Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma.

Blood advances

相似文献

同项目论文

Blood advances

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma.

Blood advances

相似文献

同项目论文

Blood advances

相关期刊

检索历史清除